Resources
9 Results (showing 1 - 9)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/17/2021 (updated 4/10/2024)
Medication-assisted treatment (MAT) is the use of medications, combined with counseling, to treat substance use disorders. Research has proven the effectiveness of MAT and addiction treatment experts endorse it, but a variety of barriers have prevented the widespread use of MAT. These include a lack of financing for medication, insufficient organizational infrastructure to deliver medication, state and county funding and regulatory obstacles, physician training and certification, staff and client resistance, and community attitudes.
Posted 3/25/2021 (updated 4/5/2024)
Care Coordination: Navigating Individuals With OUD Through a Treatment and Recovery Continuum
Presenters from the Western Region will describe two innovative care coordination strategies and models from the RCORP/Rural Health Opioid Program grantee perspective.
Posted 3/25/2021 (updated 4/5/2024)
Posted 7/9/2020 (updated 3/28/2024)
This presentation provides tips using examples from the Medicare Rural Hospital Flexibility Program on working with subcontractors, stakeholders and partners in ways to demonstrate outcomes.
Posted 8/11/2020 (updated 3/28/2024)
Sonoran Prevention Works is an advocate for people in Arizona affected by drug use. Spanish language resources from Ssamaritan PAWZ are included.
Posted 7/22/2020 (updated 3/28/2024)
New York State's Opioid Overdose Prevention Program Resources
Posted 4/25/2023 (updated 3/27/2024)
Wish lists for consortiums or coalitions often include words like “effective,” “engaged,” “productive,” “sustainable,” “powerful,” “growing,” and “motivated.”
Posted 9/25/2023 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) now has the "Engaging Community Coalitions to Decrease Opioid Overdose Deaths Practice Guide" available, as a product of the HEALing Communities Study (HCS).
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).